Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Lancet Oncol

Retrieve available abstracts of 195 articles:
HTML format



Single Articles


    April 2021
  1. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2021;22:489-498.
    PubMed     Abstract available


    March 2021
  2. PICCART M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, et al
    70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Lancet Oncol. 2021 Mar 12. pii: S1470-2045(21)00007.
    PubMed     Abstract available


  3. ANDERSON BO, Ilbawi AM, Fidarova E, Weiderpass E, et al
    The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases.
    Lancet Oncol. 2021 Mar 5. pii: S1470-2045(21)00071.
    PubMed    


  4. AMIR E, Cescon DW
    Pembrolizumab monotherapy in metastatic triple-negative breast cancer.
    Lancet Oncol. 2021 Mar 4. pii: S1470-2045(21)00019.
    PubMed    


  5. WINER EP, Lipatov O, Im SA, Goncalves A, et al
    Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2021 Mar 4. pii: S1470-2045(20)30754.
    PubMed     Abstract available


  6. CARRASCOSA MF, Fernandez-Ayala M, Cano Hoz M, Abascal Carrera I, et al
    Pathological fracture from clinically occult breast cancer.
    Lancet Oncol. 2021;22:e131.
    PubMed    


    February 2021
  7. XU B, Yan M, Ma F, Hu X, et al
    Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2021 Feb 11. pii: S1470-2045(20)30702.
    PubMed     Abstract available


  8. RYZHOV A, Corbex M, Pineros M, Barchuk A, et al
    Comparison of breast cancer and cervical cancer stage distributions in ten newly independent states of the former Soviet Union: a population-based study.
    Lancet Oncol. 2021 Feb 5. pii: S1470-2045(20)30674.
    PubMed     Abstract available


  9. VILLARREAL-GARZA C, Aranda-Gutierrez A, Ferrigno AS, Platas A, et al
    The challenges of breast cancer care in Mexico during health-care reforms and COVID-19.
    Lancet Oncol. 2021;22:170-171.
    PubMed    


  10. POORTMANS PM, Weltens C, Kirkove C
    Indications for individual internal mammary node irradiation - Authors' reply.
    Lancet Oncol. 2021;22:e41.
    PubMed    


  11. QIU PF, Wang XE, Wang YS
    Indications for individual internal mammary node irradiation.
    Lancet Oncol. 2021;22:e40.
    PubMed    


  12. WILLIAMSON L
    More women dismissing breast reconstruction after mastectomy.
    Lancet Oncol. 2021;22:e43.
    PubMed    


    January 2021
  13. MAYER EL, Dueck AC, Martin M, Rubovszky G, et al
    Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
    Lancet Oncol. 2021 Jan 15. pii: S1470-2045(20)30642.
    PubMed     Abstract available


  14. XU B, Fan Y
    CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?
    Lancet Oncol. 2021 Jan 15. pii: S1470-2045(20)30757.
    PubMed    


  15. MORGAN AJ, Giannoudis A, Palmieri C
    The genomic landscape of breast cancer brain metastases: a systematic review.
    Lancet Oncol. 2021;22:e7-e17.
    PubMed     Abstract available


  16. DUBSKY P, Pinker K, Cardoso F, Montagna G, et al
    Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox.
    Lancet Oncol. 2021;22:e18-e28.
    PubMed     Abstract available


  17. TOI M, Imoto S, Ishida T, Ito Y, et al
    Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2021;22:74-84.
    PubMed     Abstract available


  18. DENT R, Rugo HS
    Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum.
    Lancet Oncol. 2021;22:27-28.
    PubMed    


  19. TAN AR, Im SA, Mattar A, Colomer R, et al
    Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Lancet Oncol. 2021;22:85-97.
    PubMed     Abstract available


  20. BARTSCH R, Minichsdorfer C, Kolberg-Liedtke C
    Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?
    Lancet Oncol. 2021;22:5-6.
    PubMed    


    December 2020
  21. CROZIER JA, Pezzi TA, Hodge C, Janeva S, et al
    Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
    Lancet Oncol. 2020;21:1611-1619.
    PubMed     Abstract available


  22. CURIGLIANO G, Pravettoni G
    Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer.
    Lancet Oncol. 2020;21:1543-1545.
    PubMed    


  23. BISWAS D, Ganeshalingam J, Wan JCM
    The future of liquid biopsy.
    Lancet Oncol. 2020;21:e550.
    PubMed    


    November 2020
  24. POORTMANS PM, Weltens C, Fortpied C, Kirkove C, et al
    Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial.
    Lancet Oncol. 2020 Nov 2. pii: S1470-2045(20)30472.
    PubMed     Abstract available


  25. COLES CE, Haviland JS, Kirby AM
    Internal mammary node irradiation in breast cancer: does benefit outweigh risk?
    Lancet Oncol. 2020 Nov 2. pii: S1470-2045(20)30551.
    PubMed    


  26. KOPANS DB
    Recommendations for breast cancer screening.
    Lancet Oncol. 2020;21:e513.
    PubMed    


  27. YAFFE MJ, Gordon PB, Linver MN
    Recommendations for breast cancer screening.
    Lancet Oncol. 2020;21:e512.
    PubMed    


  28. TABAR L, Dean PB
    Recommendations for breast cancer screening.
    Lancet Oncol. 2020;21:e511.
    PubMed    


  29. DUFFY SW, Sasieni PD
    Mammography screening for breast cancer-the UK Age trial - Authors' reply.
    Lancet Oncol. 2020;21:e510.
    PubMed    


  30. DONZELLI A, Giudicatti G, Sghedoni D
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e509.
    PubMed    


  31. NAROD SA
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e508.
    PubMed    


  32. GERA R, Michell MJ, Mokbel K
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e507.
    PubMed    


  33. JATOI I
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e506.
    PubMed    


  34. AL-SHAMSI HO
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e505.
    PubMed    


  35. BELL KJL, Irwig L, Nickel B, Hersch J, et al
    Mammography screening for breast cancer-the UK Age trial.
    Lancet Oncol. 2020;21:e504.
    PubMed    


  36. MILLER AB
    Recommendations for breast cancer screening - Author's reply.
    Lancet Oncol. 2020;21:514.
    PubMed    


  37. PRAT A, Guarneri V, Pare L, Griguolo G, et al
    A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Lancet Oncol. 2020;21:1455-1464.
    PubMed     Abstract available


  38. SMITH I, Robertson J, Kilburn L, Wilcox M, et al
    Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.
    Lancet Oncol. 2020;21:1443-1454.
    PubMed     Abstract available


  39. HURVITZ SA
    HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer.
    Lancet Oncol. 2020;21:1392-1393.
    PubMed    


  40. MUNOZ M, Prat A
    Implementing preoperative endocrine therapy in breast cancer.
    Lancet Oncol. 2020;21:1390-1392.
    PubMed    


  41. KAIDAR-PERSON O, Kuhn T, Poortmans P
    Residual disease after mastectomy - Authors' reply.
    Lancet Oncol. 2020;21:e501.
    PubMed    


  42. WU ZY, Han J, Eom JS, Ahn SH, et al
    Residual disease after mastectomy.
    Lancet Oncol. 2020;21:e500.
    PubMed    


  43. BUNDRED NJ, Dodwell D, Bundred JR, Cutress RI, et al
    Residual disease after mastectomy.
    Lancet Oncol. 2020;21:e499.
    PubMed    


    October 2020
  44. HSU A, Matera R, Dizon DS
    Stewart-Treves syndrome: a rapidly fatal complication of breast cancer treatment.
    Lancet Oncol. 2020;21:e495.
    PubMed    


  45. EMENS LA, Esteva FJ, Beresford M, Saura C, et al
    Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
    Lancet Oncol. 2020;21:1283-1295.
    PubMed     Abstract available


    September 2020
  46. TURNER NC, Kingston B, Kilburn LS, Kernaghan S, et al
    Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Lancet Oncol. 2020 Sep 10. pii: S1470-2045(20)30444.
    PubMed     Abstract available


  47. BOURLOND F, Lipsker D
    Multiple brown papules at the site of mastectomy for breast cancer.
    Lancet Oncol. 2020;21:e460.
    PubMed    


    August 2020
  48. TELLI ML
    BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
    Lancet Oncol. 2020 Aug 27. pii: S1470-2045(20)30431.
    PubMed    


  49. DIERAS V, Han HS, Kaufman B, Wildiers H, et al
    Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2020 Aug 27. pii: S1470-2045(20)30447.
    PubMed     Abstract available


  50. DUFFY SW, Vulkan D, Cuckle H, Parmar D, et al
    Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
    Lancet Oncol. 2020 Aug 12. pii: S1470-2045(20)30398.
    PubMed     Abstract available


  51. MILLER AB
    Final results of the UK Age trial on breast cancer screening age.
    Lancet Oncol. 2020 Aug 12. pii: S1470-2045(20)30428.
    PubMed    


  52. DOMCHEK SM, Postel-Vinay S, Im SA, Park YH, et al
    Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Lancet Oncol. 2020 Aug 6. pii: S1470-2045(20)30324.
    PubMed     Abstract available


  53. WEBER WP, Morrow M, Boniface J, Pusic A, et al
    Knowledge gaps in oncoplastic breast surgery.
    Lancet Oncol. 2020;21:e375-e385.
    PubMed     Abstract available


  54. KAIDAR-PERSON O, Kuhn T, Poortmans P
    Should we worry about residual disease after mastectomy?
    Lancet Oncol. 2020;21:1011-1013.
    PubMed    


    July 2020
  55. MARINGE C, Spicer J, Morris M, Purushotham A, et al
    The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
    Lancet Oncol. 2020 Jul 20. pii: S1470-2045(20)30388.
    PubMed     Abstract available


  56. MALEKPOUR M, Widger J
    Radiation-induced angiosarcoma in a patient with breast cancer.
    Lancet Oncol. 2020;21:e369.
    PubMed    


    May 2020
  57. JONES RH, Casbard A, Carucci M, Foxley A, et al
    Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
    Lancet Oncol. 2020;21:e234.
    PubMed    


  58. LUDMIR EB, McCaw ZR, Kim DH, Tian L, et al
    Fulvestrant plus capivasertib for metastatic breast cancer.
    Lancet Oncol. 2020;21:e233.
    PubMed    


  59. DEKKER TJA
    Fulvestrant plus capivasertib for metastatic breast cancer.
    Lancet Oncol. 2020;21:e232.
    PubMed    


  60. BENSON JR
    Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ.
    Lancet Oncol. 2020;21:612-614.
    PubMed    


  61. KING MT, Link EK, Whelan TJ, Olivotto IA, et al
    Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    Lancet Oncol. 2020;21:685-698.
    PubMed     Abstract available


    April 2020
  62. BATTISTI NML, Ring A
    CDK4/6 inhibition in HER2-positive breast cancer.
    Lancet Oncol. 2020 Apr 27. pii: S1470-2045(20)30164.
    PubMed    


  63. TOLANEY SM, Wardley AM, Zambelli S, Hilton JF, et al
    Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Lancet Oncol. 2020 Apr 27. pii: S1470-2045(20)30112.
    PubMed     Abstract available


  64. THOMPSON AM
    Breast conservation therapy versus mastectomy for breast cancer.
    Lancet Oncol. 2020;21:493-494.
    PubMed    


  65. ROYCE TJ, Gupta GP, Marks LB
    Breast conservation therapy versus mastectomy for breast cancer.
    Lancet Oncol. 2020;21:492-493.
    PubMed    


    March 2020
  66. LAMBERTINI M, Vaz-Luis I
    Is HER2-positive metastatic breast cancer still an incurable disease?
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30058.
    PubMed    


  67. SWAIN SM, Miles D, Kim SB, Im YH, et al
    Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(19)30863.
    PubMed     Abstract available


  68. STIRRUPS R
    Pembrolizumab for triple-negative breast cancer.
    Lancet Oncol. 2020 Mar 5. pii: S1470-2045(20)30154.
    PubMed    


  69. GAO JJ, Cheng J, Beaver JA, Prowell TM, et al
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply.
    Lancet Oncol. 2020;21:e131.
    PubMed    


  70. PALA L, Conforti F, Goldhirsch A
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.
    Lancet Oncol. 2020;21:e130.
    PubMed    


  71. COLEMAN R, Zhou Y, Chan A
    Adjuvant denosumab in early breast cancer - Authors' reply.
    Lancet Oncol. 2020;21:e125.
    PubMed    


  72. FUSCO V, Campisi G, Bedogni A
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e124.
    PubMed    


  73. DE BOISSIEU P, Trenque T
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e123.
    PubMed    


  74. SCIMECA M, Bonfiglio R, Urbano N, Schillaci O, et al
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e122.
    PubMed    


  75. PETERS N, Conroy M, O'Reilly S
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e121.
    PubMed    


    February 2020
  76. JONES RH, Casbard A, Carucci M, Cox C, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30817.
    PubMed     Abstract available


  77. NASRAZADANI A, Brufsky AM
    Capivasertib inhibits a key pathway in metastatic breast cancer.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30857.
    PubMed    


    January 2020
  78. NUZZOLESE I, Montemurro F
    Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
    Lancet Oncol. 2020;21:21-24.
    PubMed    


    December 2019
  79. GOURD K
    San Antonio Breast Cancer Symposium 2019.
    Lancet Oncol. 2019 Dec 19. pii: S1470-2045(19)30830.
    PubMed    


  80. CURIGLIANO G, Loibl S
    CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30808.
    PubMed    


  81. GAO JJ, Cheng J, Bloomquist E, Sanchez J, et al
    CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30804.
    PubMed     Abstract available


  82. CRISTOFANILLI M
    Time for a shift in molecular down staging in luminal breast cancer.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30806.
    PubMed    


  83. PRAT A, Saura C, Pascual T, Hernando C, et al
    Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30786.
    PubMed     Abstract available


  84. COLEMAN R, Finkelstein DM, Barrios C, Martin M, et al
    Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2019 Dec 2. pii: S1470-2045(19)30687.
    PubMed     Abstract available


  85. PERRONE F, Gravina A
    Denosumab in early breast cancer: negative data and a call to action.
    Lancet Oncol. 2019 Dec 2. pii: S1470-2045(19)30717.
    PubMed    


    November 2019
  86. WOODWARD WA
    Building momentum for subsets of patients with advanced triple-negative breast cancer.
    Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30737.
    PubMed    


  87. SCHMID P, Rugo HS, Adams S, Schneeweiss A, et al
    Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30689.
    PubMed     Abstract available


    October 2019
  88. PARK YH, Kim TY, Kim GM, Kang SY, et al
    Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 tr
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30565.
    PubMed     Abstract available


  89. DAS M
    Promising radiotherapy classifier for early breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30720.
    PubMed    


  90. ROBERT M, Turner N
    Endocrine-based therapy versus chemotherapy in advanced breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30686.
    PubMed    


  91. STIRRUPS R
    Abemaciclib plus fulvestrant for breast cancer.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30629.
    PubMed    


    September 2019
  92. GOEL S, Tolaney SM
    CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30627.
    PubMed    


  93. TAN AR, Wright GS, Thummala AR, Danso MA, et al
    Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30616.
    PubMed     Abstract available


  94. GIULIANO M, Schettini F, Rognoni C, Milani M, et al
    Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Lancet Oncol. 2019 Sep 4. pii: S1470-2045(19)30420.
    PubMed     Abstract available


  95. NAROD SA
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc).
    Lancet Oncol. 2019;20:e465.
    PubMed    


  96. ZOLNIKOV TR, Chambers D
    Barriers to treatment for patients with breast cancer in Kenya.
    Lancet Oncol. 2019;20:1206-1207.
    PubMed    


    August 2019
  97. GOURD E
    Pyrotinib versus lapatinib in HER2-positive breast cancer.
    Lancet Oncol. 2019 Aug 30. pii: S1470-2045(19)30568.
    PubMed    


  98. JACKISCH C
    Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer.
    Lancet Oncol. 2019 Aug 8. pii: S1470-2045(19)30500.
    PubMed    


  99. SAURA C, Hlauschek D, Oliveira M, Zardavas D, et al
    Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Lancet Oncol. 2019 Aug 8. pii: S1470-2045(19)30334.
    PubMed     Abstract available


    June 2019
  100. BANERJI U, van Herpen CML, Saura C, Thistlethwaite F, et al
    Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
    Lancet Oncol. 2019 Jun 27. pii: S1470-2045(19)30328.
    PubMed     Abstract available


  101. SAADATMAND S, Geuzinge HA, Rutgers EJT, Mann RM, et al
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30275.
    PubMed     Abstract available


  102. KUHL CK
    Underdiagnosis is the main challenge in breast cancer screening.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30314.
    PubMed    


  103. BURKI TK
    Night shift work and breast cancer.
    Lancet Oncol. 2019 Jun 6. pii: S1470-2045(19)30383.
    PubMed    


  104. TERRY MB, Liao Y, Hopper JL, MacInnis RJ, et al
    Performance of BCRAT in high-risk patients with breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:e286.
    PubMed    


  105. GAIL MH
    Performance of BCRAT in high-risk patients with breast cancer.
    Lancet Oncol. 2019;20:e285.
    PubMed    


    May 2019
  106. STIRRUPS R
    Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30372.
    PubMed    


  107. DAS M
    GM1 for taxane-induced neuropathy in breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30373.
    PubMed    


  108. VARATHARAJAH R
    Breast cancer screening by visually impaired women.
    Lancet Oncol. 2019 May 10. pii: S1470-2045(19)30290.
    PubMed    


  109. HOFVIND S, Holen AS, Aase HS, Houssami N, et al
    Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Lancet Oncol. 2019 May 8. pii: S1470-2045(19)30161.
    PubMed     Abstract available


  110. BRANDAO M, Debiasi M, de Azambuja E
    Denosumab in early-stage breast cancer.
    Lancet Oncol. 2019;20:e234-e235.
    PubMed    


  111. RODRIGUEZ EG, Aubry-Rozier B, Stoll D, Lamy O, et al
    Denosumab in early-stage breast cancer.
    Lancet Oncol. 2019;20:e233.
    PubMed    


  112. GNANT M, Pfeiler G, Frantal S
    Denosumab in early-stage breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:236.
    PubMed    


    April 2019
  113. TAMURA K, Tsurutani J, Takahashi S, Iwata H, et al
    Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Lancet Oncol. 2019 Apr 29. pii: S1470-2045(19)30097.
    PubMed     Abstract available


  114. WANDER SA, Spring LM, Bardia A
    Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30279.
    PubMed    


  115. JIANG Z, Li W, Hu X, Zhang Q, et al
    Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30164.
    PubMed     Abstract available


  116. BURKI TK
    Fulvestrant plus anastrozole for metastatic breast cancer.
    Lancet Oncol. 2019 Apr 4. pii: S1470-2045(19)30217.
    PubMed    


    March 2019
  117. DAS M
    Supplemental ultrasonography for breast cancer screening.
    Lancet Oncol. 2019 Mar 28. pii: S1470-2045(19)30211.
    PubMed    


  118. STIRRUPS R
    Neratinib and capecitabine for breast cancer brain metastases.
    Lancet Oncol. 2019 Mar 22. pii: S1470-2045(19)30184.
    PubMed    


  119. CHAE SY, Ahn SH, Kim SB, Han S, et al
    Diagnostic accuracy and safety of 16alpha-[(18)F]fluoro-17beta-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.
    Lancet Oncol. 2019 Mar 4. pii: S1470-2045(18)30936.
    PubMed     Abstract available


  120. MANKOFF DA, Clark AS
    PET oestrogen receptor imaging: ready for the clinic?
    Lancet Oncol. 2019 Mar 4. pii: S1470-2045(19)30038.
    PubMed    


  121. ESTEVA FJ, Hubbard-Lucey VM, Tang J, Pusztai L, et al
    Immunotherapy and targeted therapy combinations in metastatic breast cancer.
    Lancet Oncol. 2019;20:e175-e186.
    PubMed     Abstract available


  122. CATANIA G, Ghirotto L, Leo SD, Timmins F, et al
    What a picture can tell you about surviving breast cancer.
    Lancet Oncol. 2019;20:335.
    PubMed    


    February 2019
  123. STIRRUPS R
    Sacituzumab govitecan-hziy for triple-negative breast cancer.
    Lancet Oncol. 2019 Feb 28. pii: S1470-2045(19)30074.
    PubMed    


  124. TERRY MB, Liao Y, Whittemore AS, Leoce N, et al
    10-year performance of four models of breast cancer risk: a validation study.
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(18)30902.
    PubMed     Abstract available


  125. GARCIA-CLOSAS M, Chatterjee N
    Assessment of breast cancer risk: which tools to use?
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(19)30071.
    PubMed    


  126. GNANT M, Pfeiler G, Steger GG, Egle D, et al
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30862.
    PubMed     Abstract available


  127. LIPPMAN M
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30913.
    PubMed    


  128. PEOPLES GE
    Improving the outcomes of checkpoint inhibitors in breast cancer.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(19)30068.
    PubMed    


  129. LOI S, Giobbie-Hurder A, Gombos A, Bachelot T, et al
    Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(18)30812.
    PubMed     Abstract available


    January 2019
  130. WANG SL, Fang H, Song YW, Wang WH, et al
    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Lancet Oncol. 2019 Jan 30. pii: S1470-2045(18)30813.
    PubMed     Abstract available


  131. SAAD ED, Squifflet P, Burzykowski T, Quinaux E, et al
    Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30750.
    PubMed     Abstract available


  132. AMIR E
    Endpoint selection in HER2-positive early breast cancer.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30779.
    PubMed    


  133. GOURD E
    Degarelix improves suppression of ovarian function.
    Lancet Oncol. 2019 Jan 11. pii: S1470-2045(19)30001.
    PubMed    


    December 2018
  134. BURKI TK
    T-DM1 for residual, invasive, HER2-positive breast cancer.
    Lancet Oncol. 2018 Dec 13. pii: S1470-2045(18)30918.
    PubMed    


    November 2018
  135. VAN RAMSHORST MS, van der Voort A, van Werkhoven ED, Mandjes IA, et al
    Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30570.
    PubMed     Abstract available


    October 2018
  136. VELIKOVA G, Williams LJ, Willis S, Dixon JM, et al
    Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
    Lancet Oncol. 2018 Oct 15. pii: S1470-2045(18)30515.
    PubMed     Abstract available


  137. YAFFE MJ
    Towards improving accuracy, effectiveness, and efficiency in breast cancer screening.
    Lancet Oncol. 2018 Oct 12. pii: S1470-2045(18)30589.
    PubMed    


    September 2018
  138. GOURD E
    Lurbinectedin for BRCA-mutated advanced breast cancer.
    Lancet Oncol. 2018 Sep 27. pii: S1470-2045(18)30737.
    PubMed    


  139. STIRRUPS R
    Atezolizumab for metastatic triple-negative breast cancer.
    Lancet Oncol. 2018 Sep 20. pii: S1470-2045(18)30706.
    PubMed    


  140. KUERER HM
    More evidence for further minimisation of breast-cancer surgery.
    Lancet Oncol. 2018 Sep 5. pii: S1470-2045(18)30416.
    PubMed    


  141. GALIMBERTI V, Cole BF, Viale G, Veronesi P, et al
    Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Lancet Oncol. 2018 Sep 5. pii: S1470-2045(18)30380.
    PubMed     Abstract available


  142. PE M, Dorme L, Coens C, Basch E, et al
    Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
    Lancet Oncol. 2018;19:e459-e469.
    PubMed     Abstract available


    August 2018
  143. GUNJUR A
    Talazoparib for BRCA-mutated advanced breast cancer.
    Lancet Oncol. 2018 Aug 23. pii: S1470-2045(18)30650.
    PubMed    


  144. GOURD E
    New triple-negative breast cancer risk genes identified.
    Lancet Oncol. 2018 Aug 16. pii: S1470-2045(18)30614.
    PubMed    


  145. DERLIN T, Hueper K
    CXCR4-targeted therapy in breast cancer.
    Lancet Oncol. 2018;19:e370.
    PubMed    


  146. NICHOLLS E
    Breast cancer in a Renaissance Book of the Dead.
    Lancet Oncol. 2018;19:1023-1024.
    PubMed    


  147. GOURD E
    Mammography deficiencies: the result of poor positioning.
    Lancet Oncol. 2018;19:e385.
    PubMed    


    July 2018
  148. MARTIN M
    The LILAC trial and the blooming of anticancer biosimilars.
    Lancet Oncol. 2018;19:861-863.
    PubMed    


    June 2018
  149. BURKI TK
    Variations in breast cancer treatment and outcomes.
    Lancet Oncol. 2018 Jun 14. pii: S1470-2045(18)30451.
    PubMed    


  150. VON MINCKWITZ G, Colleoni M, Kolberg HC, Morales S, et al
    Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30241.
    PubMed     Abstract available


    May 2018
  151. MURTHY R, Borges VF, Conlin A, Chaves J, et al
    Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30256.
    PubMed     Abstract available


  152. FOUKAKIS T
    Ribociclib in premenopausal women with advanced breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30367.
    PubMed    


  153. TRIPATHY D, Im SA, Colleoni M, Franke F, et al
    Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30292.
    PubMed     Abstract available


  154. BURKI TK
    Responses to carboplatin in BRCA1/2-mutated breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30407.
    PubMed    


  155. GOURD E
    Low uptake of tamoxifen to prevent breast cancer.
    Lancet Oncol. 2018 May 3. pii: S1470-2045(18)30344.
    PubMed    


    April 2018
  156. PERNAS S, Martin M, Kaufman PA, Gil-Martin M, et al
    Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Lancet Oncol. 2018 Apr 26. pii: S1470-2045(18)30147.
    PubMed     Abstract available


  157. SCHAFER R, Strnad V, Polgar C, Uter W, et al
    Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
    Lancet Oncol. 2018 Apr 20. pii: S1470-2045(18)30195.
    PubMed     Abstract available


  158. ECCLES DM, Copson ER
    Genetic testing for young women with breast cancer - Authors' reply.
    Lancet Oncol. 2018;19:e183.
    PubMed    


  159. METCALFE K, Akbari MR, Narod SA
    Genetic testing for young women with breast cancer.
    Lancet Oncol. 2018;19:e182.
    PubMed    


    March 2018
  160. MCGALE P, Dodwell D, Taylor C, Gray R, et al
    Neoadjuvant chemotherapy for early breast cancer - Author's reply.
    Lancet Oncol. 2018;19:e130.
    PubMed    


  161. KRUG D, Loibl S
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e129.
    PubMed    


  162. CHARALAMPOUDIS P, Karakatsanis A
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e128.
    PubMed    


    February 2018
  163. CURIGLIANO G
    Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30129.
    PubMed    


  164. LOIBL S, O'Shaughnessy J, Untch M, Sikov WM, et al
    Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111.
    PubMed     Abstract available


  165. DE PLACIDO S, Gallo C, De Laurentiis M, Bisagni G, et al
    Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 23. pii: S1470-2045(18)30116.
    PubMed     Abstract available


  166. WILDIERS H, Tryfonidis K, Dal Lago L, Vuylsteke P, et al
    Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Lancet Oncol. 2018 Feb 9. pii: S1470-2045(18)30083.
    PubMed     Abstract available


  167. BIANUCCI R, Perciaccante A, Charlier P, Appenzeller O, et al
    Earliest evidence of malignant breast cancer in Renaissance paintings.
    Lancet Oncol. 2018;19:166-167.
    PubMed    


    January 2018
  168. FASCHING PA
    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(18)30008.
    PubMed    


  169. COPSON ER, Maishman TC, Tapper WJ, Cutress RI, et al
    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Lancet Oncol. 2018 Jan 11. pii: S1470-2045(17)30891.
    PubMed     Abstract available


  170. GIANNI L, Bisagni G, Colleoni M, Del Mastro L, et al
    Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30001.
    PubMed     Abstract available


  171. PIVOT X, Cox DG
    A new era for treatment development in HER2-positive breast cancer.
    Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30002.
    PubMed    


  172. MALAGA G, Cuba-Fuentes S, Romero-Albino Z
    Implementation of a community-based breast cancer management programme.
    Lancet Oncol. 2018;19:e3.
    PubMed    


  173. GLIGOROV J
    Early HER2-positive breast cancers: time for a new revolution?
    Lancet Oncol. 2018;19:12-13.
    PubMed    


  174. CHLEBOWSKI RT, Pan K
    Complexity of intermittent letrozole adjuvant therapy.
    Lancet Oncol. 2018;19:13-15.
    PubMed    


    December 2017
  175. BURKI TK
    Improved progression-free survival in metastatic breast cancer.
    Lancet Oncol. 2017 Dec 21. pii: S1470-2045(17)30952.
    PubMed    


  176. NELSON R
    San Antonio Breast Cancer Symposium 2017.
    Lancet Oncol. 2017 Dec 14. pii: S1470-2045(17)30930.
    PubMed    


  177. DERKS MGM, van de Velde CJH
    Neoadjuvant chemotherapy in breast cancer: more than just downsizing.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30914.
    PubMed    



  178. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
    Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30777.
    PubMed     Abstract available


  179. SALGADO R, Loi S
    Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30905.
    PubMed    


  180. DENKERT C, von Minckwitz G, Darb-Esfahani S, Lederer B, et al
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30904.
    PubMed     Abstract available


  181. DI LEO A, Johnston S, Lee KS, Ciruelos E, et al
    Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Dec 6. pii: S1470-2045(17)30688.
    PubMed     Abstract available


  182. HO AY, Hu ZI, Mehrara BJ, Wilkins EG, et al
    Radiotherapy in the setting of breast reconstruction: types, techniques, and timing.
    Lancet Oncol. 2017;18:e742-e753.
    PubMed     Abstract available


    November 2017
  183. HURVITZ SA, Martin M, Symmans WF, Jung KH, et al
    Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2017 Nov 23. pii: S1470-2045(17)30716.
    PubMed     Abstract available


  184. COLLEONI M, Luo W, Karlsson P, Chirgwin J, et al
    Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2017 Nov 17. pii: S1470-2045(17)30715.
    PubMed     Abstract available


  185. MARTIN M, Holmes FA, Ejlertsen B, Delaloge S, et al
    Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30717.
    PubMed     Abstract available


  186. CHAVEZ-MACGREGOR M, Mittendorf EA
    Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.
    Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30844.
    PubMed    


  187. GOURD E
    Thermography should not be used in breast cancer screening.
    Lancet Oncol. 2017 Nov 2. pii: S1470-2045(17)30833.
    PubMed    


    October 2017
  188. COSTA L, Ferreira AR
    Adjuvant zoledronic acid to treat breast cancer: not for all.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30695.
    PubMed    


  189. COLEMAN R, Hall A, Albanell J, Hanby A, et al
    Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
    Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30603.
    PubMed     Abstract available


  190. GOURD E
    Insulin analog linked to breast cancer risk.
    Lancet Oncol. 2017 Oct 5. pii: S1470-2045(17)30772.
    PubMed    


  191. DUGGAN C, Dvaladze AL, Tsu V, Jeronimo J, et al
    Resource-stratified implementation of a community-based breast cancer management programme in Peru.
    Lancet Oncol. 2017;18:e607-e617.
    PubMed     Abstract available


  192. PINEROS M, Ramos W, Antoni S, Abriata G, et al
    Cancer patterns, trends, and transitions in Peru: a regional perspective.
    Lancet Oncol. 2017;18:e573-e586.
    PubMed     Abstract available


    September 2017
  193. GOURD E
    Pyrotinib shows activity in metastatic breast cancer.
    Lancet Oncol. 2017 Sep 21. pii: S1470-2045(17)30755.
    PubMed    


    August 2017
  194. KERR J, Anderson C, Lippman SM
    Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
    Lancet Oncol. 2017;18:e457-e471.
    PubMed     Abstract available


  195. LEVIS BE, Binkley PF, Shapiro CL
    Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Lancet Oncol. 2017;18:e445-e456.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: